IL226116B - Pharmaceutical preparations containing lipid compounds for the treatment of high apo b- - Google Patents

Pharmaceutical preparations containing lipid compounds for the treatment of high apo b-

Info

Publication number
IL226116B
IL226116B IL226116A IL22611613A IL226116B IL 226116 B IL226116 B IL 226116B IL 226116 A IL226116 A IL 226116A IL 22611613 A IL22611613 A IL 22611613A IL 226116 B IL226116 B IL 226116B
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical compositions
lipid compounds
elevated apo
apo
Prior art date
Application number
IL226116A
Other languages
English (en)
Hebrew (he)
Other versions
IL226116A0 (en
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of IL226116A0 publication Critical patent/IL226116A0/en
Publication of IL226116B publication Critical patent/IL226116B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/60—Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL226116A 2010-11-05 2013-05-02 Pharmaceutical preparations containing lipid compounds for the treatment of high apo b- IL226116B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41044510P 2010-11-05 2010-11-05
PCT/IB2011/002925 WO2012059818A1 (en) 2010-11-05 2011-11-03 Methods of treatment using lipid compounds

Publications (2)

Publication Number Publication Date
IL226116A0 IL226116A0 (en) 2013-06-27
IL226116B true IL226116B (en) 2018-01-31

Family

ID=46024069

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226116A IL226116B (en) 2010-11-05 2013-05-02 Pharmaceutical preparations containing lipid compounds for the treatment of high apo b-

Country Status (22)

Country Link
US (1) US9394228B2 (enExample)
EP (1) EP2635270B1 (enExample)
JP (1) JP2014505017A (enExample)
KR (3) KR20200034814A (enExample)
CN (2) CN107496395A (enExample)
AR (1) AR083772A1 (enExample)
AU (1) AU2011324909B2 (enExample)
BR (1) BR112013010890B1 (enExample)
CA (1) CA2816949C (enExample)
CO (1) CO6771414A2 (enExample)
EA (1) EA028535B1 (enExample)
ES (1) ES2618604T3 (enExample)
IL (1) IL226116B (enExample)
MX (1) MX350720B (enExample)
MY (1) MY170076A (enExample)
NZ (1) NZ610705A (enExample)
PH (1) PH12013500893A1 (enExample)
SG (2) SG10201509127YA (enExample)
TW (2) TW201701875A (enExample)
UA (1) UA111475C2 (enExample)
WO (1) WO2012059818A1 (enExample)
ZA (1) ZA201303813B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
NZ596386A (en) 2009-05-08 2014-01-31 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
UA111475C2 (uk) 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
HRP20170383T1 (hr) 2013-02-28 2017-05-05 Pronova Biopharma Norge As Postupak za pripravu 2-((5z,8z,11z,14z,17z)-ikoza-5,8,11,14,17-pentaeniloksi)butanske kiseline
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
RU2705991C2 (ru) * 2015-04-01 2019-11-13 Пронова Биофарма Норге Ас Применение тиаоксосоединений для уменьшения содержания аро с3
JP7341916B2 (ja) * 2015-04-01 2023-09-11 ビーエーエスエフ エーエス アポｃ３を低下させるためのチアオキソ化合物の使用
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
EP3720431B1 (en) 2017-12-06 2024-10-30 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
AU2021405273A1 (en) * 2020-12-22 2023-08-10 Northsea Therapeutics B.V. Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909554A (en) 1956-07-23 1959-10-20 Monsanto Chemicals Process for the manufacture of (alkylmercapto) alkyl sulfates
GB1038723A (enExample) 1962-03-26
JPS4839001B1 (enExample) 1970-11-09 1973-11-21
US4040781A (en) 1974-06-06 1977-08-09 Lever Brothers Company Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same
US4032564A (en) 1974-09-09 1977-06-28 Zoecon Corporation Esters of cyclopropylalkanols
GB1523276A (en) 1974-09-20 1978-08-31 Lafon Labor Sulphur-containing amino compounds
US4009211A (en) 1975-07-29 1977-02-22 Gulf Research & Development Company Beta,beta-dialkylethylmercaptoethoxylate as new compounds
US4209410A (en) 1976-04-28 1980-06-24 Phillips Petroleum Company Lubricants
EP0002007B1 (de) 1977-11-11 1982-07-28 Ciba-Geigy Ag Neue Pyridindicarbonsäureesterderivate und ihre Gemische mit metallhaltigen Stabilisatoren sowie ihre Verwendung zur Stabilisierung von chlorhaltigen Thermoplasten
JPS5570841A (en) 1978-11-24 1980-05-28 Konishiroku Photo Ind Co Ltd Forming method of dye image
US4368190A (en) 1980-04-17 1983-01-11 Merck & Co., Inc. Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation
US4444766A (en) 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
US4411808A (en) 1982-08-04 1983-10-25 Exxon Research & Engineering Co. Multifunctional additive for power transmission shift fluids
US4775223A (en) 1984-09-20 1988-10-04 Canon Kabushiki Kaisha Lactic acid derivative, liquid crystal composition containing same and liquid crystal device
CA2010000A1 (en) 1989-04-07 1990-10-07 Paul B. Merkel Photographic recording material containing a cyan dye-forming coupler
JPH0451149A (ja) 1990-06-19 1992-02-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
FR2663928B1 (fr) 1990-06-27 1994-04-08 Norsolor Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres.
EP0487809A1 (en) 1990-11-28 1992-06-03 Monsanto Europe S.A./N.V. Rubber compositions having improved processability and improved rubber-vulcanisate properties
JPH0543529A (ja) 1991-08-10 1993-02-23 Taisho Pharmaceut Co Ltd アルカンアミドアンモニウム化合物
JP2755279B2 (ja) 1992-03-19 1998-05-20 三井化学株式会社 熱可塑性樹脂組成物およびその成形体
JP2793458B2 (ja) 1992-03-19 1998-09-03 三井化学株式会社 コネクター用ポリアミド系樹脂組成物およびコネクター
EP0702556B1 (en) 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
JP3110918B2 (ja) 1993-06-18 2000-11-20 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
GB2290789B (en) 1994-07-01 1998-09-16 Ciba Geigy Ag Titanium and zirconium complexes of carboxylic acids as corrosion inhibitors
ATE210640T1 (de) 1994-10-13 2001-12-15 Peptide Technology Ltd Modifizierte mehrfach ungesättigte fettsäuren
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
FR2741619B1 (fr) 1995-11-28 1998-02-13 Pf Medicament Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
CA2251780A1 (en) 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fatty acids
US6060515A (en) 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
BR9806989A (pt) 1997-01-24 2000-03-14 Univ California Processo para tratar a epiderme ou membrana da mucosa de um indivìduo mamìfero.
JPH11180929A (ja) 1997-12-19 1999-07-06 Asahi Glass Co Ltd エステル誘導体
AU7240398A (en) 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
FR2786187B1 (fr) 1998-11-19 2001-11-09 Univ Paris Curie Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations
FR2792312B1 (fr) 1999-04-15 2001-06-08 Oreal Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
JP2003500459A (ja) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター 置換バイアリールエーテル化合物
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
FR2828487B1 (fr) 2001-08-09 2005-05-27 Genfit S A Nouveaux composes derives d'acides gras, preparation et utilisations
US20030147814A1 (en) 2001-12-21 2003-08-07 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
GB2383355A (en) 2001-12-22 2003-06-25 Schlumberger Holdings An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant
GB0202002D0 (en) 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
BR0307265B1 (pt) 2002-01-31 2012-11-27 composição substancialmente isenta de solvente, emulsão concentrada, e processo para tratamento e conferência de repelência à água a materiais fibrosos, couro, peles e têxteis.
JP2005533057A (ja) 2002-06-13 2005-11-04 ニューヨーク・ユニバーシティ 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用
FR2845991B1 (fr) 2002-10-16 2005-02-04 Pf Medicament Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
WO2004076404A1 (ja) 2003-02-28 2004-09-10 Kaneka Corpration ２位に置換基を有する光学活性化合物の製造法
DE10326303A1 (de) 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
WO2005073164A1 (en) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
JP4563114B2 (ja) 2004-08-30 2010-10-13 出光興産株式会社 潤滑剤用添加剤
CA2599673A1 (en) 2005-03-08 2006-09-14 Reinhold Oehrlein Metal oxide nanoparticles coated with specific n-acylaminomethylene phosphonates
EP1888728A4 (en) 2005-05-04 2010-07-14 Pronova Biopharma Norge As Fatty acid analogues, D.H. DHA DERIVATIVES FOR USE AS A MEDICAMENT
CN101213281B (zh) 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
US20070167529A1 (en) 2006-01-17 2007-07-19 Walton Rebecca A Antimicrobial compositions for treating fabrics and surfaces
ES2391305T3 (es) 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
EP1849449A1 (en) 2006-04-26 2007-10-31 3M Innovative Properties Company Filler containing composition and process for production and use thereof
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2007133653A2 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
JP5552313B2 (ja) 2006-11-01 2014-07-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物
MX2009004337A (es) 2006-11-01 2009-05-22 Pronova Biopharma Norge As Compuestos lipidos omega-3.
WO2008053340A1 (en) 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
CN101225064A (zh) 2007-01-19 2008-07-23 上海汇瑞生物科技有限公司 一种制备β-硫杂-α-烷基脂肪酸的新方法
DE102007017179A1 (de) 2007-04-12 2008-10-23 Clariant International Ltd. Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation
EP2217558A1 (en) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS New dha derivatives and their use as medicaments
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
CN101259118B (zh) * 2008-01-31 2010-06-16 中国科学院广州生物医药与健康研究院 2’,4’-二羟基-6’-甲氧基-3’,5’-二甲基查耳酮作为PPARγ激动剂的应用
WO2009149496A1 (en) * 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
FR2933006B1 (fr) 2008-06-27 2010-08-20 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
KR101708065B1 (ko) 2008-07-08 2017-02-17 카타베이시스 파마슈티칼즈, 인코포레이티드 지방산 아세틸화 살리실레이트 및 그 용도
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
PH12019500030A1 (en) 2009-03-09 2020-02-10 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
EP2248798A1 (en) * 2009-05-08 2010-11-10 Pronova BioPharma Norge AS Novel lipid compounds
NZ596386A (en) 2009-05-08 2014-01-31 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CN102724877B (zh) 2009-09-01 2015-05-13 凯特贝希制药公司 脂肪酸烟酸缀合物及其用途
JP2013517322A (ja) 2010-01-20 2013-05-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス サリチレート脂肪酸誘導体
UA111475C2 (uk) 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2013016531A2 (en) 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer

Also Published As

Publication number Publication date
MY170076A (en) 2019-07-03
TWI578984B (zh) 2017-04-21
EA028535B1 (ru) 2017-11-30
KR102265409B1 (ko) 2021-06-16
SG190114A1 (en) 2013-07-31
EA201390659A1 (ru) 2013-11-29
AR083772A1 (es) 2013-03-20
KR20190072661A (ko) 2019-06-25
CA2816949C (en) 2017-07-04
CA2816949A1 (en) 2012-05-10
AU2011324909A1 (en) 2013-06-13
WO2012059818A1 (en) 2012-05-10
CO6771414A2 (es) 2013-10-15
AU2011324909B2 (en) 2016-09-08
ES2618604T3 (es) 2017-06-21
JP2014505017A (ja) 2014-02-27
EP2635270A1 (en) 2013-09-11
CN103347508A (zh) 2013-10-09
EP2635270A4 (en) 2014-03-26
EP2635270B1 (en) 2016-12-21
KR20200034814A (ko) 2020-03-31
SG10201509127YA (en) 2015-12-30
ZA201303813B (en) 2015-06-24
PH12013500893A1 (en) 2013-07-15
MX2013005022A (es) 2013-06-03
UA111475C2 (uk) 2016-05-10
US9394228B2 (en) 2016-07-19
TW201233388A (en) 2012-08-16
BR112013010890A2 (pt) 2016-08-02
CN107496395A (zh) 2017-12-22
US20130345269A1 (en) 2013-12-26
NZ610705A (en) 2014-10-31
TW201701875A (zh) 2017-01-16
IL226116A0 (en) 2013-06-27
MX350720B (es) 2017-09-14
KR20130132836A (ko) 2013-12-05
BR112013010890B1 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
IL276012A (en) Pharmaceutical preparations containing sorbitan esters
IL226116B (en) Pharmaceutical preparations containing lipid compounds for the treatment of high apo b-
EP2568975A4 (en) FILM COMPOSITIONS FOR THE DISTRIBUTION OF ACTIVE SUBSTANCES
EP2629786A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS
PL2560624T3 (pl) Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
ZA201403795B (en) Formulations for the treatment of diabetes
HU1000069D0 (en) New salts for the preparation of pharmaceutical composition
ZA201400501B (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
EP2661273A4 (en) IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
PT2773348T (pt) Composição farmacêutica de omeprazol
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
HUP1000624A2 (en) Novel salts suitable for the preparation of pharmaceutical compositions
AU2011900519A0 (en) Drug compositions for the treatment of insomnia
SG11201401570YA (en) Pharmaceutical compositions of resveratrol
IL223324A0 (en) Novel pharmaceutical compounds
IL232294A0 (en) Preparations for the treatment of diabetes
GB201010671D0 (en) Compounds for treatment of inflammation
GB201005495D0 (en) Compounds for treatment of inflammation
GB201001216D0 (en) Pharmaceutical compounds
GB201003950D0 (en) Pharmaceutical compounds
GB201005734D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed